NCT06427798
Somatostatin-Receptors (SSTR)-Agonist [212Pb]VMT-alpha-NET in Metastatic or Inoperable SSTR+ Gastrointestinal Neuroendocrine Tumor and Pheochromocytoma/Paraganglioma Previously Treated With Systemic Targeted Radioligand Therapy treatment 1 / 2 not_yet_recruiting NCT02186678
Comparison of Diagnostic Performances of 68Ga-DOTATATE PET-CT and 18F-FDOPA PET-CT in Paragangliomas and Pheochromocytomas Evaluation No drug interventions diagnostic Not Available completed NCT01347307
Stereotactic Body Radiotherapy for Spine Tumors No drug interventions treatment Not Available completed NCT05636618
Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors No drug interventions treatment 1 / 2 recruiting NCT06607692
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined with the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). treatment 2 recruiting NCT02834013
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors treatment 2 active_not_recruiting NCT06233903
18F-mFBG Expression in Neural Crest Tumors and Organs Innervated by the Sympathetic Nervous System diagnostic 2 not_yet_recruiting NCT03206060
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma treatment 2 recruiting NCT05142241
Testing the Combination of Anti-Cancer Drugs Talazoparib and Temozolomide in Patients With Advanced Stage Rare Cancers, RARE 2 Trial treatment 2 suspended NCT06573723
Institutional Registry of Rare Diseases No drug interventions Not Available Not Available recruiting NCT01413503
A Phase II Study of 131I- Metaiodobenzylguanidine (MIBG) for Treatment of Metastatic or Unresectable Pheochromocytoma and Related Tumors No drug interventions treatment 2 completed NCT01838187
Expanded Access Protocol Using 131I-MIBG Therapy +/- Vorinostat for Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma Not Available Not Available no_longer_available NCT06377033
Using the EHR to Advance Genomic Medicine Across a Diverse Health System No drug interventions health_services_research Not Available recruiting NCT03839498
Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma treatment 2 recruiting NCT05082311
Cardiac and Vascular Changes in Pheochromocytoma and Paraganglioma No drug interventions Not Available Not Available completed NCT05418907
Exendin PET/CT for Imaging of Paragangliomas No drug interventions Not Available Not Available recruiting NCT01022515
Specificity of Elevated Plasma EM66 Levels in Pheochromocytoma No drug interventions Not Available Not Available completed NCT01941849
Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma treatment 1 withdrawn NCT01373736
123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors No drug interventions diagnostic 3 unknown_status NCT00188019
Hereditary Paraganglioma: Evaluation of Screening Methods to Detect Tumors in SDH Positive Carriers No drug interventions diagnostic Not Available completed NCT05451134
Predictors and Outcomes of Dysglycemia in Pheochromocytoma and Paraganglioma No drug interventions Not Available Not Available unknown_status NCT04119024
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors treatment 1 recruiting NCT04573816
Development of a Tele-monitoring Program for Patients Undergoing Surgery for Pheochromocytoma and / or Paraganglioma No drug interventions Not Available Not Available unknown_status NCT04711135
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs treatment 2 active_not_recruiting NCT04605848
Infrared Thermography Associated With Cutaneous Microcirculation for Detection of Brown-adipose Tissue (MICROBAT) No drug interventions diagnostic Not Available terminated NCT03160274
Genetic Analysis of Pheochromocytomas, Paragangliomas and Associated Conditions No drug interventions Not Available Not Available recruiting NCT04400474
Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN Study treatment 2 active_not_recruiting NCT06523582
Genetic Bases of Neuroendocrine Neoplasms in Mexican Patients No drug interventions Not Available Not Available recruiting NCT04788927
Development of a Predictive Model for the Risk of Metastatic Disease in PPGLs, a Retrospective Cohort Study No drug interventions Not Available Not Available not_yet_recruiting NCT03946527
LAnreotide in Metastatic Pheochromocytoma / PARAganglioma (LAMPARA) treatment 2 recruiting NCT01560260
Linsitinib in Treating Patients With Gastrointestinal Stromal Tumors treatment 2 completed NCT00911729
Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma No drug interventions Not Available Not Available terminated NCT04081701
68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors. No drug interventions diagnostic 4 recruiting NCT04187404
A Novel Therapeutic Vaccine (EO2401) in Metastatic Adrenocortical Carcinoma, or Malignant Pheochromocytoma/Paraganglioma treatment 1 / 2 active_not_recruiting NCT03165721
A Phase II Trial of the DNA Methyl Transferase Inhibitor, Guadecitabine (SGI-110), in Children and Adults With Wild Type GIST,Pheochromocytoma and Paraganglioma Associated With Succinate Dehydrogenase Deficiency and HLRCC-associated Kidney Cancer treatment 2 terminated NCT04276597
Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET. treatment 2 withdrawn NCT03583528
DOTATOC PET/CT for Imaging NET Patients No drug interventions Not Available Not Available recruiting NCT03176693
Preoperative Alpha Blockade for Pheochromocytoma treatment 3 completed NCT05233878
Prognostic's Factors of Head and Neck Paragangliomas Evolution No drug interventions Not Available Not Available recruiting NCT06444607
Hereditary Pheochromocytoma Assessment of Tumour Immunologies No drug interventions Not Available Not Available not_yet_recruiting NCT05883085
A Study on the Safety and Effectiveness of Anlotinib for Neoadjuvant Treatment of PPGL treatment 2 recruiting NCT02431715
18F-FDOPA PET in Neuroendocrine Tumours No drug interventions Not Available Not Available no_longer_available NCT00843037
Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma treatment 2 completed NCT05948137
F-18 FDOPA PET/CT Versus I-123 MIBG Scintigraphy With SPECT/CT for the Diagnosis of Pheochromocytoma and Paraganglioma No drug interventions Not Available Not Available terminated NCT01377532
Compassionate Use of 131I-MIBG for Patients With Malignant Pheochromocytoma Not Available Not Available approved_for_marketing NCT00458952
Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma treatment 1 / 2 completed NCT06155734
Fluorescence Guided Minimally-Invasive Resection Of Abdominal Paragangliomas Using Indocyanine Green Not Available Not Available recruiting NCT03344016
Multicenter Pheochromocytoma and Paraganglioma Evaluation No drug interventions health_services_research Not Available recruiting NCT05885386
A Study on the Safety and Effectiveness of Temozolomide for Neoadjuvant Treatment of PPGL treatment 2 recruiting NCT06440122
The Incidence and Outcomes of Metabolically Active Brown Adipose Tissue (aBAT) in Patients With Pheochromocytoma or Paraganglioma (PPGLs) No drug interventions Not Available Not Available recruiting NCT03923257
Dosimetry Guided PRRT With 177Lu-DOTATATE in Children and Adolescents treatment 1 / 2 withdrawn NCT05069220
18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor diagnostic 0 recruiting NCT00339131
ULTRATRACE Iobenguane I 131 in Patients With Malignant Pheochromocytoma, Paraganglioma, or Metastatic Carcinoid diagnostic 1 completed NCT02177773
GA-68 DOTA-TOC of Somatostatin Positive Malignancies diagnostic 1 / 2 terminated NCT01967576
Phase II Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Metastatic, Recurrent or Primary Unresectable Pheochromocytoma/Paraganglioma treatment 2 completed NCT01204476
Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine Carcinoma treatment 1 completed NCT06045260
"Receptor Radionuclide Therapy With 177Lu-DOTATOC treatment 2 recruiting NCT01340794
Pazopanib Hydrochloride in Treating Patients With Advanced or Progressive Malignant Pheochromocytoma or Paraganglioma treatment 2 terminated NCT02961491
Expanded Access Program of Ultratrace Iobenguane I131 for Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma Not Available Not Available approved_for_marketing NCT01590680
Expanded Access Protocol Using 131I-MIBG No drug interventions Not Available Not Available available NCT05702944
The Effect and Safety of Omitting Preoperative Alpha-adrenergic Blockade for Normotensive Pheochromocytoma prevention 4 recruiting NCT05636540
In Vivo PARP-1 Expression With 18F-FluorThanatrace PET/CT in Patients With Pheochromocytoma and Paraganglioma No drug interventions diagnostic 0 recruiting NCT04017104
Dynamic Whole Body Positron Emission Tomography/Computed Tomography Imaging No drug interventions Not Available Not Available unknown_status NCT04891081
Plasma Metanephrines in Patients With Cyanotic and Acyanotic Congenital Heart Disease No drug interventions Not Available Not Available unknown_status NCT00874614
A Study Evaluating Ultratrace Iobenguane I131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma No drug interventions treatment 2 unknown_status